Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells

• Verfasst von: Hohaus, Stefan [VerfasserIn]
• Verfasst von: Martin, H. [VerfasserIn]
• Verfasst von: Waßmann, Barbara [VerfasserIn]
• Verfasst von: Egerer, Gerlinde [VerfasserIn]
• Verfasst von: Haus, U. [VerfasserIn]
• Verfasst von: Färber, L. [VerfasserIn]
• Verfasst von: Burger, K. J. [VerfasserIn]
• Verfasst von: Goldschmidt, Hartmut [VerfasserIn]
• Verfasst von: Hoelzer, D. [VerfasserIn]
• Verfasst von: Haas, Rainer [VerfasserIn]
• Titel: Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells
• Verf.angabe: S. Hohaus, H. Martin, B. Wassmann, G. Egerer, U. Haus, L. Färber, K.J. Burger, H. Goldschmidt, D. Hoelzer, and R. Haas
• E-Jahr: 1998
• Jahr: 09 October 1998
• Umfang: 6 S.
• Fussnoten: Gesehen am 23.04.2025
• Titel Quelle: Enthalten in: Bone marrow transplantation
• Ort Quelle: London : Springer Nature, 1997
• Jahr Quelle: 1998
• Band/Heft Quelle: 22(1998), 7, Seite 625-630
• ISSN Quelle: 1476-5365
• DOI: doi:10.1038/sj.bmt.1701422
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Cell Biology
• Sach-SW: general
• Sach-SW: Hematology
• Sach-SW: Internal Medicine
• Sach-SW: Medicine/Public Health
• Sach-SW: Public Health
• Sach-SW: Stem Cells
• K10plus-PPN: 1923462318

Abstract

The availability of hematopoietic growth factors has greatly facilitated the mobilization and collection of peripheral blood stem cells (PBSC). It was the aim of this double-blind study to compare the PBSC-mobilizing efficacy of recombinant human G-CSF and GM-CSF when administered post-chemotherapy. Twenty-six patients with relapsed Hodgkin’s disease were included in the study. Their median age was 31 years (range, 22-59) and 14 patients were males and 12 were females. Patients were pretreated with a median of eight cycles of cytotoxic chemotherapy, while 18 patients had undergone extended field irradiation. The patients received dexamethasone 24 mg days 1-7, melphalan 30 mg/m2 day 3, BCNU 60 mg/m2 day 3, etoposide 75 mg/m2 days 4-7, Ara-C 100 mg/m2 twice daily days 4-7 (Dexa-BEAM). Twelve patients were randomized to receive 5 μg/kg/day G-CSF and 14 patients to receive 5 μg/kg/day GM-CSF, both administered subcutaneously starting on day 1 after the end of Dexa-BEAM. Primary endpoints of the study were the number of CD34+ cells harvested per kg body weight on the occasion of six consecutive leukaphereses and the time needed for hematological reconstitution following autografting. Twenty-one patients completed PBSC collection, and six patients of the G-CSF group and nine of the GM-CSF group were autografted. No difference was observed with respect to the median yield of CFU-GM and CD34+ cells: 32.5 × 104/kg vs 31.3 × 104/kg CFU-GM, and 7.6 × 106/kg vs 5.6 × 106/kg CD34+ cells, for G-CSF and GM-CSF, respectively (U test, P = 0.837 and 0.696). High-dose chemotherapy consisted of cyclophosphamide 1.7 g/m2 days 1-4, BCNU 150 mg/m2 days 1-4, etoposide 400 mg/m2 days 1-4. All patients transplanted with more than 5 × 106 CD34+ cells/kg had a rapid platelet recovery (20 × 109/l) between 6 and 11 days and neutrophil recovery (0.5 × 109/l) between 9 and 16 days, while patients transplanted with less than 5 × 106/kg had a delayed reconstitution, regardless of the kind of growth factor used for PBSC mobilization. In conclusion, our data indicate that in patients with Hodgkin’s disease G-CSF and GM-CSF given after salvage chemotherapy appear to be not different in their ability to mobilize PBSC resulting in a similar time needed for hematological reconstitution when autografted following high-dose therapy.